Introduction: The Shifting Landscape of Pediatric Visual Impairment
Cerebral/cortical visual impairment (CVI) has recently been redefined by the 2024 National Institutes of Health (NIH) CVI Working Group as a “neurodevelopmental disorder characterized by deficits of visual function and functional vision that are caused by neurologic damage to visual pathways and processing areas in the brain.“
In the modern clinical landscape, CVI is the leading cause of pediatric visual impairment in high-resource countries and is rapidly emerging as a primary cause in middle- and low-resource regions.
This shifting epidemiology is intrinsically linked to the increased survival rates of premature and critically ill neonates—a global trend observed by the World Health Organization (WHO) since 2000 through the lens of the Millennium Development Goals (MDGs) and Sustainable Development Goals (SDGs).
As clinicians, we must move beyond the historical view of CVI as merely “cortical blindness.” This update provides a comprehensive schema for the diagnosis, characterization, and multidisciplinary management of these patients, who represent a complex spectrum of neurological and visual dysfunction.
The NIH Framework: Five Key Elements of CVI
The 2024 NIH definition provides five essential pillars to guide clinical identification:
- A Spectrum of Impairment: CVI encompasses a broad range of visual deficits. A critical clinical “red flag” is the significant divergence between:
- Visual function: Quantitative clinical measures such as visual acuity (VA) and contrast sensitivity.
- Functional vision: The patient’s ability to use vision for real-world tasks and navigation.
- Clinical Pearl: A child may present with near-normal VA (lower-order processing) but struggle profoundly with environmental navigation (higher-order processing).
- Disproportionate Visual Dysfunction: The impairment is “out of proportion” to any co-occurring ocular findings. While a patient may have comorbid optic nerve pallor, the degree of visual loss is significantly greater than the nerve’s appearance would suggest.
- Afferent Deficits and Characteristic Behaviors: Dysfunction can involve lower-order pathways (eye to primary occipital cortex) or higher-order pathways (visual association areas), leading to specific behavioral profiles.
- Distinct from Primary Learning Disorders: CVI often co-occurs with Autism Spectrum Disorder (ASD), ADHD, and dyslexia. However, CVI is a primary sensory-processing deficit, not a disorder of language or communication. While facial recognition issues in CVI may mimic ASD, or visual search difficulties may simulate ADHD-related inattention, specific assessment tools are required to disentangle these visual processing deficits from primary neurodevelopmental conditions.
- Occult or Delayed Presentation: The inciting neurological insult typically occurs during early brain development but may remain masked by general developmental delays until later in childhood.
Etiology and Risk Factors
A comprehensive workup must identify the neurological trigger. If the etiology is unknown, referral for neurological evaluation and neuroimaging is mandatory.
Neurological Etiologies of CVI
|
Category
|
Specific Conditions/Triggers
|
|---|---|
|
Ischemic
|
Hypoxic-ischemic encephalopathy (HIE), intraventricular hemorrhage, periventricular leukomalacia (PVL), congenital cardiac/vascular anomalies, venous stroke, sickle cell disease, hematologic abnormalities, twin-twin transfusion syndrome
|
|
Seizures
|
Infantile spasms, Lennox-Gastaut syndrome, Dravet syndrome, Ohtahara syndrome
|
|
Structural
|
Focal cortical dysplasia, hemimegalencephaly, holoprosencephaly, lissencephaly, polymicrogyria, schizencephaly, porencephaly, colpocephaly
|
|
Compressive
|
Hydrocephalus, intracranial mass lesions (tumors)
|
|
Infection
|
Meningitis, encephalitis, TORCH infections, Zika virus, subacute sclerosing panencephalitis, progressive multifocal leukoencephalopathy
|
|
Toxins/Drugs
|
Intrauterine drug exposure (cocaine, methamphetamine), chemotherapy (cisplatin, vincristine, methotrexate), immunosuppressants (cyclosporine, tacrolimus), antibiotics (metronidazole, ciprofloxacin), heavy metals (lead, mercury), Asphyxiating gas exposure (CO, NO)
|
The Role of Genetic Testing
In the absence of clear perinatal risk factors (like PVL or HIE), genetic testing is highly recommended. Research reveals a 7% prevalence of chromosomal abnormalities in the CVI population; notably, 37% of these are previously unidentified. Testing is especially indicated for patients with syndromic features, such as dysmorphic facies or epilepsy.
Clinical Presentation:
Afferent and Efferent Deficits
Lower-Order Afferent Deficits
- Acuity and Contrast: Variable decreases in VA and contrast sensitivity.
- Visual Fields: Defects correspond to the site of brain involvement (e.g., hemianopsias).
- Color Vision: Often relatively spared due to bilateral brain representation; patients may show a preference for highly saturated, bright colors.
Higher-Order Afferent Deficits
These deficits typically reflect dorsal stream dysfunction:
- Agnosias: Prosopagnosia (face blindness), topographic agnosia (inability to navigate familiar surroundings), and simultanagnosia (difficulty detecting stimuli against complex backgrounds).
- Motion Perception: Challenges with complex motion, though movement can often be used to facilitate visual attention.
- Visuospatial Perception: Impaired depth perception, including astereocognosis (difficulty with depth not explained by strabismus).
Efferent and Behavioral Characteristics
Oculomotor findings include strabismus, nystagmus, increased saccadic latency, and fixation instability.
- Gaze Patterns: Research indicates CVI gaze is driven more by low-level features (color) and less by high-level semantic features.
- Characteristic Behaviors: Eccentric gaze (looking away while reaching), compulsive light gazing or extreme photophobia, and fluctuating visual attention in unfamiliar environments.
- Differential Diagnosis: CVI must be distinguished from “look-alikes” including delayed visual maturation (DVM), amblyopia, and oculomotor apraxia.
The Diagnostic Workflow
To confirm a CVI diagnosis, five requirements must be satisfied:
- Evidence of a neurological condition impacting the developing visual pathways.
- Documentation of abnormal lower-order and/or higher-order afferent visual function.
- Documentation of abnormal functional vision.
- Ocular anatomy that is either normal or insufficient to explain the vision loss.
- In specific cases, neuropsychological assessment to differentiate CVI from other disorders (like ASD).
Neuroimaging: A Diagnostic Tool, Not a Rule-Out
Structural MRI is critical for identifying anatomic markers like PVL or hydrocephalus. However, it is a clinical maxim that a normal structural MRI does not exclude CVI. Emerging modalities like functional MRI (fMRI) and tractography are currently research-based but offer promising insight into structure-function correlations and white matter connectivity.
Assessment Modalities: From Clinic to Classroom
Clinical Measurements
For children with developmental delays, we utilize forced-choice preferential looking (FPL) and sweep visual evoked potentials (sVEP). VA is often assessed via the 6-level semi-quantitative visual behavior scale:
- Level 1: Light perception only.
- Level 2: Occasional fixation on large objects, faces, or movement.
- Level 3: Occasional fixation on small objects or reliable fixation on large objects (4-inch lighted toy at 1 foot).
- Level 4: Reliable fixation on small objects (2-inch toy at 1 foot).
- Level 5: Reliable fixation and pursuit of small objects.
- Level 6: Reliable fixation and pursuit of the smallest objects (1-inch toy at least 2 feet away).
Higher-Order and Functional Testing
Qualitative clinic tools include the Lea mailbox (line orientation), the Lea rectangle game (size perception), and the Boston cookie theft picture (simultanagnosia). Functional vision must be assessed via validated caregiver questionnaires:
|
Questionnaire Name
|
Target Patient Population/Age
|
|---|---|
|
CVI Visual Skills Inventory
|
All ages
|
|
Five Questions (Screener)
|
All ages (validated for 5–16.5 years)
|
|
Hellgren CVI Questionnaire
|
Extremely preterm infants (<27 weeks)
|
|
Flemish CVI Questionnaire
|
Children aged 3–17 years
|
|
Preverbal Visual Assessment (PreViAs)
|
Infants aged 0–2 years
|
|
Preschool CVI Screening List
|
Children aged 2–5 years
|
|
CVI Motor Questionnaire (CVI-MQ)
|
Children with Cerebral Palsy
|
Management and the Multidisciplinary Team
While there are no medical cures for CVI, the management paradigm focuses on optimization and habilitation:
- Visual Stimulation: Structured exposure to objects with varied contrast and movement to improve VA and fixation.
- Visual Habilitation: Adapting the environment (e.g., reducing visual clutter, increasing contrast) to maximize currently available functional vision.
The evidence for intervention is mounting. Fazzi et al. demonstrated that early visual training and environmental adaptation over 6 months led to significant improvements in visual acuity (3.13 cycles per degree [cpd]) compared to a comparison group (1.19 cpd), a difference significant at $P < 0.01$.
The management team must be multidisciplinary, involving Teachers of the Visually Impaired (TVIs), Occupational Therapists (OTs), and Orientation and Mobility Specialists.
Future Directions in Research
- Precision Neuroanatomy: Recent studies highlight that right thalamic and lateral pulvinar volume reduction are linked specifically to spatial navigation challenges.
- Mechanistic Insight: Research into white matter development is revealing how weaker structural and stronger functional connectivity correlate with impaired visual search.
- Objective Classification: Eye-tracking is being used to classify CVI functional groups and quantify gaze patterns objectively.
- Digital Therapeutics: The “iVision” adaptive video game suite is showing efficacy in improving visual perception through gamified rehabilitation.
- PEDIG Study: The planned natural history study will provide the longitudinal data necessary to launch future randomized clinical trials.
Conclusion: A Call for Inclusive Identification
The 2024 NIH framework represents a pivotal shift toward a standardized, inclusive approach to CVI. By bridging the gap between clinical measurements and real-world functional vision through multidisciplinary collaboration, we can significantly improve developmental trajectories and quality of life for these children. Standardizing our definitions is the first step toward universal, effective care.
Clinical Update
Cerebral / Cortical Visual Impairment (CVI) — Essentials for Ophthalmologists
The Cardinal Red Flag & Dissociation
A hallmark of CVI is disproportionate visual dysfunction not explained by ocular anatomy:
Function vs. Functional Vision: Preserved visual acuity can coexist with severe real-world navigation deficits
Structural Mismatch: Visual loss far exceeds the degree of optic disc pallor or anterior segment findings
Higher-Order & Dorsal Stream Deficits
Visual impairment frequently stems from cortical processing and association areas rather than ocular media:
- Simultanagnosia: Inability to perceive complex scenes or items in visual clutter.
- Prosopagnosia & Topographic Agnosia: Deficits in facial recognition and spatial orientation.
- Astereocognosis: Impaired depth and motion perception unexplained by strabismus.
- Oculomotor / Gaze: Eccentric gaze (“look-away while reaching”), prolonged saccadic latency, and light-gazing.
Etiologies & Imaging Maxim
Leading causes include hypoxic-ischemic encephalopathy (HIE), periventricular leukomalacia (PVL), hydrocephalus, CNS infections, and structural malformations:
- Crucial Clinical Maxim: A completely normal structural brain MRI does not rule out CVI.
- Genetic Screening: 7% have chromosomal anomalies (up to 37% novel variants), indicated especially with epilepsy or dysmorphism.
Management & Multidisciplinary Habilitation
There is no medical cure, but targeted visual stimulation and clutter reduction foster neuroplasticity:
Evidence-Based Habilitation: Early visual training yields significant grating acuity gains (Δ3.13 cpd vs 1.19 cpd, P<0.01)
Reference:
“Update on Cerebral/Cortical Visual Impairment… : International Ophthalmology Clinics.” Ovid, 3 Sept. 2026, doi:10.1097/IIO.0000000000000603.
